Skip to main content
David Albala, MD, Urology, Syracuse, NY, Crouse Health

DavidMAlbalaMDFACS

Urology Syracuse, NY

Minimally Invasive Surgery, Stone Disease

Surgeon - Associated Medical Professionals; Chief of Urology - Crouse Hospital

Dr. Albala is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Albala's full profile

Already have an account?

Education & Training

  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumFellowship, Minimally Invasive Urologic Surgery, 2000 - 2001
  • Dartmouth-Hitchcock/Mary Hitchcock Memorial Hospital
    Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Urology, 1986 - 1990
  • Dartmouth-Hitchcock/Mary Hitchcock Memorial Hospital
    Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Surgery, 1983 - 1985
  • Michigan State University College of Human Medicine
    Michigan State University College of Human MedicineClass of 1983

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1993 - 2024
  • FL State Medical License
    FL State Medical License 2011 - 2022
  • NC State Medical License
    NC State Medical License 2001 - 2010
  • NH State Medical License
    NH State Medical License 1985 - 2002
  • IL State Medical License
    IL State Medical License 1991 - 2002
  • VT State Medical License
    VT State Medical License 1985 - 1996
  • American Board of Urology Urology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2002-2014
  • America's Top Doctors for Cancer Castle Connolly, 2010-2013
  • CMS Meaningful Use Stage 1 Certification MEDENT EMR/EHR, Community Computer Service, Inc., 2012

Publications & Presentations

PubMed

Press Mentions

  • Cellanyx Publishes Clinical Proof-of-Concept Study in Urology of First-in-Class Live Tumor Cell, Phenotypic Biomarker Test to Risk Stratify Prostate Cancer Patients
    Cellanyx Publishes Clinical Proof-of-Concept Study in Urology of First-in-Class Live Tumor Cell, Phenotypic Biomarker Test to Risk Stratify Prostate Cancer PatientsNovember 21st, 2018
  • A Practice Model Designed to Reward Physician Partners Equally
    A Practice Model Designed to Reward Physician Partners EquallyDecember 14th, 2017
  • Robotic Surgery Is Milestone Advancement for Prostate Cancer Treatment
    Robotic Surgery Is Milestone Advancement for Prostate Cancer TreatmentJanuary 23rd, 2017
  • Join now to see all

Hospital Affiliations